Should a prolonged duration of dual anti-platelet therapy be recommended to patients with diabetes mellitus following percutaneous coronary intervention? A systematic review and meta-analysis of 15 studies

Table 2 General features of the studies included

Features	No of DM patients in the short term group (n)	No of DM patients in the long term group (n)	Type of study	Enrollment period	Duration of DAPT use (months)
Brar2008	378	371	OB	2002–2004	<9 vs > 9
I-LOVE IT 2	211	203	RCT	2012–2015	6 vs 12
ISAR-SAFE	495	484	RCT	2008–2014	6 vs 12
Tarantini2016	206	223	RCT	2009–2014	6 vs > 12
ARCTIC	222	198	RCT	2009–2011	<12 vs >12
OPTIMIZE	554	549	RCT	2010–2015	3 vs 12
RESET	316	305	RCT	2009–2010	3 vs 12
EXCELLENT	272	278	RCT	2008–2009	6 vs 12
PEGASUS	1950	1574	RCT	2010–2013	<12 vs > 12
DAPT	1481	1556	RCT	2009–2011	12 vs 30
Sardella2011	133	139	OB	2005–2006	12 vs > 12
PRODIGY	35	36	RCT	2006–2012	6 vs 24
Thukkani2015	6568	5949	OB	2002–2006	12 vs > 12
ENDEAVOR	198	183	RCT	2005–2011	12 vs > 24
ITALIC	331	344	RCT	2011–2015	6 vs 24
Total no of patients (n)	13,350	12,392

Abbreviations: DM diabetes mellitus, DAPT dual antiplatelet therapy, RCT randomized controlled trials, OS observational studies

ISSN: 1471-2261